Skip to content

Evaluation of Isoniazide 300mg for Latent Tuberculosis Treatment

Evaluation of implementation of 300mg isoniazide for the treatment of latent Infection of tuberculosis in Brazil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2wsdt6
Enrollment
Unknown
Registered
2018-09-10
Start date
2019-01-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent tuberculosis.

Interventions

546 individuals with a diagnosis of latent tuberculosis will participate in the study. Being 273 in the experimental group and 273 in the control group. As described below: Experimental group: take on
D02.442.436

Sponsors

Universidade Federal do Espirito Santo
Lead Sponsor
Universidade Federal do Espirito Santo
Collaborator

Eligibility

Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All individuals over 18 years of age with indication for ILTB treatment

Exclusion criteria

Exclusion criteria: Individuals whose case index is a multiresistant and extremely resistant case, as well as those individuals who were transferred from the original center after two or more weeks of treatment initiation beyond the individuals in the prison system will be excluded.In addition, people over 80 years old will be excluded.

Design outcomes

Primary

MeasureTime frame
Expected outcome: difference in number of patients who adhered to the treatment of latent tuberculosis, verified by the follow-up of the patients and the finding of at least 5% increase in the success rate to the treatment with the intervention.;Outcome found: difference in the number of patients who adhered to latent tuberculosis treatment, verified by monitoring patients and with the finding of a 19% increase in the success rate of treatment with the intervention.

Countries

Brazil

Contacts

Public ContactCarolina Sales

Universidade Federal do Espirito Santo

carolnurse@hotmail.com+55-027-33357013

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 10, 2026